{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:34:36Z","timestamp":1790678076989,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00198-021-06021-2","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T20:03:23Z","timestamp":1622750603000},"page":"2583-2586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Diffuse adverse cutaneous reactions induced by zoledronic acid administration: a case report"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1879-2363","authenticated-orcid":false,"given":"Kawtar","family":"Nassar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadia","family":"Janani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"issue":"6","key":"6021_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","volume":"44","author":"SC Cremers","year":"2005","unstructured":"Cremers SC, Pillai G, Papapoulos SE (2005) Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44(6):551\u2013570","journal-title":"Clin Pharmacokinet"},{"key":"6021_CR2","doi-asserted-by":"publisher","unstructured":"Briot K, Roux C, Thomas T, Blain H, Buchon D, Chapurlat R et al (2018) 2018 Update of French recommendations on the management of postmenopausal osteoporosis. Joint Bone Spine. https:\/\/doi.org\/10.1016\/j.jbspin.2018.02.009","DOI":"10.1016\/j.jbspin.2018.02.009"},{"key":"6021_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL, Mebrotra B, Rosenberg TJ et al (2004) Osteonecrosis of the jaws associated with the use of biphosphonates. A review of 63 cases. J Oral Maxillofac Facial Surg 62:527\u2013534","journal-title":"J Oral Maxillofac Facial Surg"},{"key":"6021_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12105-011-0313-8","volume":"6","author":"D Andreadis","year":"2012","unstructured":"Andreadis D, Mauroudis S, Poulopoulos A, Markopoulos A, Epivatianos A (2012) Lip ulceration associated with intravenous administration of zoledronic acid: report of a case. Head Neck Pathol 6:275\u2013278","journal-title":"Head Neck Pathol"},{"key":"6021_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/DAD.0000000000000341","volume":"37","author":"F Succaria","year":"2015","unstructured":"Succaria F, Collier M, Mahalingam M (2015) Zoledronic acid\u2013induced interface dermatitis. Am J Dermatopathol 37:933\u2013935","journal-title":"Am J Dermatopathol"},{"key":"6021_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1755-1536-3-6","volume":"3","author":"MA Scheper","year":"2010","unstructured":"Scheper MA, Chaisuparat R, Cullen KJ, Meiller TF (2010) A novel soft tissue in vitro model for biphosphonate-associated osteonecrosis. Fibrogenesis Tissue Repair 3:6\u201317","journal-title":"Fibrogenesis Tissue Repair"},{"key":"6021_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00784-009-0266-4","volume":"14","author":"C Walter","year":"2010","unstructured":"Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart H (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14:35\u201341","journal-title":"Clin Oral Investig"},{"issue":"6","key":"6021_CR8","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.jaad.2009.04.015","volume":"65","author":"H Kory","year":"2011","unstructured":"Kory H, Kitagawa MD (2011) and Marcelle Grassi. Zoledronate acid-induced cutaneous B-Cell pseudolymphoma. J Am Acad Dermatol 65(6):1238\u20131240","journal-title":"J Am Acad Dermatol"},{"key":"6021_CR9","unstructured":"European Medicines Agency (2008) Zoledronic acid. Summary of product characteristics. http:\/\/www.emea.europa.eu. Cited 4 Jan 2010"},{"issue":"4","key":"6021_CR10","first-page":"455","volume":"24","author":"EC Rizos","year":"2006","unstructured":"Rizos EC, Milionis HJ, Elisaf MS (2006) Fever with rash following zoledronate acid administration. Clin Exp Rheumatol 24(4):455","journal-title":"Clin Exp Rheumatol"},{"key":"6021_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00223-011-9499-8","volume":"89","author":"R Rizzoli","year":"2011","unstructured":"Rizzoli R, Reginster J-Y, Boonen S, Breart G, Felsenberg ADD, Kaufman J-M et al (2011) Adverse reactions and drug\u2013drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 89:91\u2013104","journal-title":"Calcif Tissue Int"},{"key":"6021_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00198-009-1097-5","volume":"21","author":"P Musette","year":"2010","unstructured":"Musette P, Brandi M, Cacoub J, Kaufman M, Rizzoli R, Reginster J-Y (2010) Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 21:723\u2013732","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06021-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-06021-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06021-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T07:02:37Z","timestamp":1637564557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-06021-2"}},"subtitle":["Eruptions cutan\u00e9es diffuses induites par l\u2019administration de l\u2019acide zol\u00e9dronique"],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6021"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-06021-2","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"4 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}